Comparative Pharmacology
Head-to-head clinical analysis: EKTERLY versus LARTRUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EKTERLY versus LARTRUVO.
EKTERLY vs LARTRUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ekterly is a tissue-selective estrogen receptor degrader (SERD) that binds to the estrogen receptor (ER) and induces conformational changes leading to ER degradation. It antagonizes ER-mediated gene transcription and signaling, thereby inhibiting ER-dependent breast cancer cell proliferation.
Olaratumab is a recombinant human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor alpha (PDGFRα), blocking PDGF-AA, -BB, and -CC binding and receptor activation, thereby inhibiting tumor growth.
10 mg orally once daily
10 mg/kg IV every 2 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Steady state reached within 2 days. Accumulation negligible with once-daily dosing.
Terminal elimination half-life is approximately 11 days (range 4–20 days), supporting a 3-week dosing interval when combined with doxorubicin.
Renal excretion accounts for 70% of elimination, with 30% hepatobiliary/fecal. Approximately 15% is excreted unchanged in urine; the remainder as glucuronide metabolites.
Olaratumab is cleared primarily via proteolytic catabolism; no specific renal or biliary excretion studies have been conducted. In patients, only trace amounts are excreted in urine (<1% of dose).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent